Lifeline Biotechnologies Prepares to File New Patent on Breast Cancer Detection
RENO, Nev.--Lifeline Biotechnologies, Inc. (Pink Sheets:LBTN) today announced that it is nearing a patent filing on its major breakthrough technology in the early detection of breast cancer.
Jim Holmes, CEO of Lifeline Biotechnologies, stated that "This technology advance has the potential of revolutionizing the way, timing and results this breakthrough holds in the assistance of detection of breast cancer. It means that, potentially, breast cancer could be identified in a greater number of patients, that is the accuracy could reduce the number of false positives and also reduce the number of needless biopsies. There are approximately 35 million mammograms a year in the United States. From which there are approximately one million biopsies. From this number of biopsies, approximately 200,000 to 250,000 cancers are identified. In other words, there are some 750,000 to 800,000 biopsies from which there are no cancers. We think our system has the potential of substantially reducing this number."
About Lifeline Biotechnologies, Inc.:
Lifeline Biotechnologies, Inc. is a company with innovative medical technologies committed to the improvement of the quality of life through exceptional health care systems. These technologies focus on prevention, early detection, diagnosis and quick recovery of a number of disease conditions. The company's technologies, designed to assist in the early detection of cancers, deal with cutting edge innovation to assist practicing physicians in the delivery of quality medical care.
SAFE HARBOR: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
Contacts
Lifeline Biotechnologies, Inc.
Investor Relations
Rodney Marvel, 1-866-THE-APPLE
www.lbtn.com
Jim Holmes, CEO of Lifeline Biotechnologies, stated that "This technology advance has the potential of revolutionizing the way, timing and results this breakthrough holds in the assistance of detection of breast cancer. It means that, potentially, breast cancer could be identified in a greater number of patients, that is the accuracy could reduce the number of false positives and also reduce the number of needless biopsies. There are approximately 35 million mammograms a year in the United States. From which there are approximately one million biopsies. From this number of biopsies, approximately 200,000 to 250,000 cancers are identified. In other words, there are some 750,000 to 800,000 biopsies from which there are no cancers. We think our system has the potential of substantially reducing this number."
About Lifeline Biotechnologies, Inc.:
Lifeline Biotechnologies, Inc. is a company with innovative medical technologies committed to the improvement of the quality of life through exceptional health care systems. These technologies focus on prevention, early detection, diagnosis and quick recovery of a number of disease conditions. The company's technologies, designed to assist in the early detection of cancers, deal with cutting edge innovation to assist practicing physicians in the delivery of quality medical care.
SAFE HARBOR: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
Contacts
Lifeline Biotechnologies, Inc.
Investor Relations
Rodney Marvel, 1-866-THE-APPLE
www.lbtn.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.